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INTRODUCTION
Cervical cancer is the primary cancer of the cer-
vix (cervical canal and/or portio). Cervical cancer
ranks first in overall cancer incidence in Indone-
sian women.1 Approximately 70% of cervical can-
cer patients came at advanced stage (> II-B). Re-
Abstract
Objective: To compare the sensitivity and specificity of Squamous
Cell Carcinoma (SCC) and Vascular Endothelial Growth Factor
(VEGF) levels to assess the response of radiation therapy.
Method: The study was conducted by the method of analytic obser-
vational cohort study in 24 patients with cervical cancer stage II-B
and III-B in RSCM that met inclusion criteria. Examination of VEGF
and SCC in serum samples was performed in the Prodia Laboratory
Jakarta. The examination was conducted twice before and after ra-
diation therapy. The subjects were treated by radiation therapy/
chemoradiation according to standard procedures. After the com-
pletion of radiation was declared, the response of radiation therapy
was conducted by clinical assessment.
Result: Of the 24 subjects, we obtained a mean level of SCC pre-ra-
diation was 23.43 ± 5.84 ng/ml and post-radiation was 2.19 ± 0.68
ng/ml. The mean VEGF pre-radiation was 790.41 ± 111.06 pg/ml
and post-radiation was 497.47 ± 79.26 pg/ml. ROC curves of each tu-
mor marker obtained SCC pre-radiation AUC 40%, p 0.53 (CI 0.18-
0.68) and SCC post-radiation AUC 48.1%, p 0.91 (CI 0.21-0,75) can
not be used as a diagnostic and prognostic factors of response to ra-
diation therapy. VEGF pre-radiation produced an AUC of 17.5%, p
0.04 (CI 0.00-0.36), thus cannot be used as a prognostic factor for re-
sponse to radiation therapy. VEGF after radiation produced an AUC
of 92.5%, p 0.01 (CI 0.81-1.00), thus can be a diagnostic factor for
response to radiation therapy. VEGF post-radiation with cut-off
point 614.75 pg/ml had a sensitivity 80%, specificity 75%, NDP
94.12%, NDN 42.86%; RKP 3.2; RKN 0.26 and accuracy 79.16%.
There is a significant correlation between the decrease of serum
VEGF level post-radiation and a positive response of radiation the-
rapy (p 0.01, CI 1.00-3.23).
Conclusion: Examination of VEGF levels can be used to assess the
response of radiation therapy with a sensitivity of 80% and specifi-
city of 75%.
[Indones J Obstet Gynecol 2014; 2-1: 40-45]
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Abstrak
Tujuan: Penelitian ini bertujuan membandingkan sensitivitas dan
spesifisitas kadar SCC dengan VEGF untuk menilai respons terapi ra-
diasi.
Metode: Penelitian dengan metode studi kohort analitik observasional
terhadap 24 subjek penelitian yaitu penderita kanker serviks stadium
II-B dan III-B di RSCM yang memenuhi kriteria inklusi. Pemeriksaan
VEGF dan SCC pada sampel serum dilakukan di Lab. Prodia Pusat Ja-
karta, sebanyak dua kali pemeriksaan yaitu sebelum dan sesudah te-
rapi radiasi. Subjek ditatalaksana dengan terapi radiasi/kemoradiasi
sesuai prosedur standar. Setelah terapi dinyatakan selesai, kemudian
dilakukan penilaian respons terapi secara klinis.
Hasil: Dari 24 subjek penelitian didapatkan rerata kadar petanda tu-
mor SCC praradiasi 23,43 ± 5,84 ng/ml dan pascaradiasi 2,19 ± 0,68
ng/ml. Rerata VEGF praradiasi 790,41 ± 111,06 pg/ml dan pascara-
diasi 497,47 ± 79,26 pg/ml. Dari kurva ROC masing-masing petanda
tumor didapatkan SCC praradiasi AUC 40%; p 0,53 (IK 0,18-0,68) dan
SCC pascaradiasi AUC 48,1%; p 0,91 (IK 0,21-0,75) tidak dapat dipakai
sebagai faktor prognostik maupun diagnostik terhadap respons terapi
radiasi pada kanker serviks. VEGF praradiasi AUC 17,5%; p 0,04 (IK
0,00-0,36) tidak dapat dipakai sebagai faktor prognostik terhadap
respons terapi radiasi pada kanker serviks. VEGF pascaradiasi AUC
92,5%; p 0,01 (IK 0,81-1,00) dapat menjadi faktor diagnostik terhadap
respons terapi radiasi pada kanker serviks. VEGF pascaradiasi dengan
titik potong (cut-off point) 614,75 pg/ml memiliki sensitivitas 80%;
spesifisitas 75%; NDP 94,12%; NDN 42,86%; RKP 3,2; RKN 0,26 dan
akurasi 79,16%. Terdapat korelasi bermakna antara penurunan ka-
dar serum VEGF pascaterapi dengan respons radiasi positif (p 0,01; IK
1,00-3,23).
Kesimpulan: Pemeriksaan kadar VEGF dapat digunakan untuk meni-
lai respons terapi radiasi dengan sensitivitas 80% dan spesifisitas
75%.
[Maj Obstet Ginekol Indones 2014; 2-1: 40-45]
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search by Sarika (2006) found from the 465 new
cases of cervical cancer, most cases were diagnosed
as stage III-B with the most common histopathol-
ogy was squamous cell carcinoma.2
Primary therapy of advanced cervical cancer is
radiation. But radiation therapy is known to be
able to cause complications, such as fibrosis that
causes stiffness in the radiated tissue. Advanced
cervical cancer generally have a large tumor size
and extension. Radiation therapy may not kill can-
cer cells in the central region. Assessment of clini-
cal response is based solely on the findings of the
response at the surface, so it will face obstacles in
the face of treatment response. One method to as-
sess treatment response is the examination of tu-
mor markers.
SCC antigen is a tumor marker for the presence
of squamous cells that produce serine protease in-
hibitor. Some studies found that serum SCC can be
used to monitor the onset of cervical squamous cell
carcinoma after primary therapy. SCC serum levels
were still high and an increase after treatment
showed a tumor or progressive disease. Using a
cut-off value of SCC 3.0 ng/ml Strauss HG (2002)
et al detect levels of serum SCC antigen pre-opera-
tive as an independent prognostic factor in squa-
mous cell cervical cancer, both of reccurence-free
and overall survival. From the analysis concluded
that SCC antigen as tumor markers correlate with
prognosis in operability of cervical cancer, tumor
size, status of pelvic nodes, cervical stromal infil-
tration, and the degree of spread of the tumor into
the parametrium.3
Hong JH (1998) et al who examined the levels
of squamous cell carcinoma (SCC) found that levels
of SCC antigen > 10 ng/ml is an independent pre-
dictor of poor prognosis in cervical cancer and can
be used as a prognostic factor in selecting patients
for intensive therapy. SCC levels were still high af-
ter radiation therapy is a strong predictor of treat-
ment failure.4
Vascular endothelial growth factor (VEGF) plays
an important role in tumor angiogenesis by in-
creasing vascular permeability, endothelial cell
growth, proliferation, migration and differentia-
tion. VEGF can also facilitate the extravasation of
tumor cells and then metastasize by way of de-
stroying the tumor extracellular matrix wall by ac-
tivating the proteolytic enzymes.5
Although a lot of evidence to suggest that VEGF
plays a role in microinvasion at an early stage,
there has been no extensive studies to assess VEGF
expression as a prognostic factor in locally ad-
vanced cervical cancer, including radiation therapy
outcomes.6,7
Evaluation of the expression levels of VEGF are
also useful in assessing response to therapy, such
as post-radical hysterectomy, chemoradiation, and
even monitor the results of treatment with anti-
angiogenesis drugs. This research was undertaken
to assess whether serum VEGF levels have prog-
nostic value and can be used in the treatment of
cervical cancer patient.8,9
As tumor markers both VEGF and SCC need to
be explored to determine which one is more sen-
sitive and specific for assessing response to radia-
tion therapy in cervical cancer.
METHODS
This study was a cohort study, which examined the
serum levels of VEGF and SCC antigen in patients
with cervical cancer stage IIB - IIIB before and after
radiation therapy. The objective was to determine
the relationship between the serum level of VEGF
and SCC with radiation therapy response and then
compare the sensitivity and specificity of VEGF and
SCC to the response of radiation therapy.
The study population was all cervical cancer pa-
tients who came to RSUPN Dr. Cipto Mangun-
kusumo Jakarta with the following inclusion crite-
ria, clinical stage IIB-IIIB (according to FIGO) with
histopathology results squamous cell carcinoma;
underwent chemoradiation/radiation; does not
have any other systemic diseases that affect the
levels of serum SCC antigen and VEGF and has not
received treatment for cancer.
Patients were managed by chemoradiation or
radiation in accordance with the study protocol. Af-
ter chemoradiation or radiation has completed, an-
other venous blood sampling was taken again
about 2 (two) weeks after radiation therapy com-
pleted, to examine VEGF and SCC antigen serum
levels and do clinical examination to assess the re-
sponse of chemoradiation therapy.
Chemoradiation or radiation therapy response is
a clinical response obtained from clinical examina-
tion 1 month after chemoradiation or radiation
therapy is complete, consisting of complete res-
ponse, partial response, no response/stable and
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progressive. In this study, interpretation was di-
vided into two groups of responses, positive res-
ponse = complete response and negative response
= response beside complete response.
RESULTS
The study subjects was 24 patients with advanced
cervical cancer, which comprised of 9 patients
stage II-B and 15 patients stage III-B. The tumor
markers, Squamous Cell Carcinoma Antigen (SCC
antigen) and Vascular Endothelial Growth Factor
(VEGF), was measured twice, before and after ra-
diation. The mean level of SCC pre-radiation was
23.43 ± 5.84 ng/ml and post-radiation was 2.19 ±
0.68 ng/ml, and the mean level of VEGF pre-radia-
tion was 790.41 ± 111.06 pg/ml and post-radiation
was 497.47 ± 79.26 pg/ml.
Measurement of tumor markers pre-radiation
was performed to assess whether the SCC and
VEGF could be used as a prognostic factor of res-
ponse to radiation therapy. While the post-radia-
tion was examined to assess whether the SCC and
VEGF have diagnostic value to replace the clinical
judgement that had been done before. Based on
measurements using ROC curves, we obtained re-
spectively SCC tumor markers and VEGF for thera-
peutic response. (Table 1)
Table 1. Results of ROC Curves of Tumor Markers and
Response of Radiation Therapy
Tumor markers AUC (%) p CI 95%
SCC:
Pre-radiation 40.0 0.53 0.18 - 0.68
Post-radiation 48.1 0.91 0.21 - 0.75
VEGF:
Pre-radiation 17.5 0.04 0.00 - 0.36
Post-radiation 92.5 0.01 0.81 - 1.00
AUC: area under curve
VEGF post-radiation with AUC 92.5% results,
show that VEGF levels are excellent (AUC> 90%)
to be used as a diagnostic factor in diagnosing re-
sponse of radiation therapy in cervical cancer with
p: 0.01 (CI: 0.81 - 1.00). (Fig. I)
To get the cut-off point of serum VEGF levels af-
ter radiation, we made a graphof VEGF sensitivity
and specificity values. (Fig. II)
Post radiation serum VEGF levels at 614.75
pg/ml had a highest sensitivity and specificity val-
ues, with sensitivity 80% and specificity 75%. Ac-
cording to the 2x2 table with a value of 614.75
pg/ml as the cut-off point on the response of ra-
diation therapy, we obtained the following results.
(Table 2)
 
Figure 1. ROC Curve of VEGF Serum Levels in Post-
radiation Patients.
 
Figure 2. Cut-off Value from Sensitivity and Specificity of
VEGF Levels in Post-Radiation Patients.
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Table 2. Diagnostic Value of VEGF (pg/ml) Post-Radia-





Positive (%) Negative (%)
≤614.75 16 94.1 1 5.9 17
>614.75 4 57.1 3 42.9 7
Total 20 83.3 4 16.7 24
From the table above, the value obtained sensi-
tivity 80%, specificity 75%, positive predictive va-
lue (PPV) 94.12%, negative predictive value (NPV)
42.86%, positive likelihood ratio (PLR) 3.2; nega-
tive likelihood ratio (NLR) 0.26 and accuracy
79.16%.
Table 3 below shows the trend of up and down
inboth serum tumor markers SCC and VEGF for
therapeutic response.
It appears that the decline in serum levels of SCC
from pre to post-radiation did not correlate with a
positive response (p 0.44; CI 0.57 to 2.92). While
the decline in serum levels of VEGF in pre and post-
radiation therapy correlated with a positive res-
ponse (p 0.01, CI 1.00 to 3.23).
DISCUSSION
Based on the pathology report in 2002, cervical
cancer ranks first out of 10 cases of most cancers
in both men and women and cancer in women
only, with a total of 2532 cases.10 From the results
of tumor markers measurements, it appears that
the SCC tumor markers can not be used to assess
response of radiation therapy. SCC pre-radiation
levels reached only 40% AUC with p: 0.53 (CI: 0.18
to 0.68). These results indicate that the SCC pre-
radiation can not be used to assess the response
to radiation therapy in cervical cancer. The SCC le-
vels reached 48.1% AUC after radiation with p:
0.91 (CI: 0.21 to 0.75) indicating that the SCC also
can not substitute the clinical assessment of thera-
peutic response.
VEGF as tumor markers was also measured be-
fore and after radiation. VEGF results obtained pre-
radiation covers only AUC 17.5%, although the p:
0.04 (CI: 0.00 - 0.36), as same as SCC, can not be
used for assessing response to radiation therapy in
cervical cancer. But VEGF post-radiation with AUC
92.5% results, show that VEGF levels are excellent
(AUC> 90%) to be used as a diagnostic factor in
diagnosing response of radiation therapy in cervi-
cal cancer with p: 0.01 (CI: 0.81 - 1.00).
Hong JH (1998) et al examined the levels of
squamous cell carcinoma (SCC) and found that le-
vels of SCC antigen > 10 ng/ml was an independent
predictor of poor prognosis in cervical cancer, and
could be used as a prognostic factor in selecting
patients for intensive therapy. High levels of SCC
antigen after radiation therapy was a strong pre-
dictor of treatment failure.4
Some studies find that serum SCC antigen can
be used to monitor the incidence of cervical squa-
mous cell carcinoma after primary therapy. SCC an-
tigen serum levels which remains high or even in-
crease after treatment showed a tumor or progres-
sive disease.3,11,12
Radiation therapy is the primary treatment mo-
dality in invasive cervical cancer and can achieve
satisfactory results in patients with early stage.
While in patients with advanced stage therapeutic
modalities are still many failures. Preliminary re-
Table 3. Classification of Tumor Markers pre and Post Radiation and Therapeutic Response.
Tumor markers
Response of radiation therapy
RR CI 95% p
Pos (%) Neg (%)
SCC:
• Increase 18 85 3 14.3 1.29 0.57 - 2.92 0.44
• Decrease 2 66.6 1 33.3
VEGF:
• Increase 15 100 0 0 1.80 1.00 - 3.23 0.01
• Decrease 5 55.6 4 44.4
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search conducted by Hong JH et al (1998) showed
that there is a failure rate of 30% in patients with
squamous cell carcinoma of the cervix with large
lesions (bulky) stage IB-IIA and IIB after definitive
radiation therapy, and will increase to 50% in pa-
tients with stage III.3,4,7
Evaluation of the expression levels of VEGF are
also useful in assessing therapeutic response, such
as post-radical hysterectomy, chemoradiation, and
even monitor the results of treatment with anti-
angiogenesis drugs.7,8
Serum levels of VEGF post-radiation with AUC
92.5% results, show that VEGF levels are excellent
(AUC > 90%) to be used as a diagnostic factor in
diagnosing response of radiation therapy in cervi-
cal cancer with p: 0.01 (CI: 0.81 - 1.00).
Cheng WF get a mean (median) intra-tumoral
VEGF protein in patients with cervical cancer was
180 pg/mg, whereas in normal tissue 0 pg/mg.
Large lesions > 4 cm than < 4cm (1030 compared
to 118). Limfo-vascular invasion than not (568
compared to 118) and patients with lymph-nodes
metastasis than without metastasis (795.5 com-
pared to 121 pg/mg). Over-expression of VEGF ob-
tained from immuno-histochemical examination of
10/20 (50%) in cases with metastatic nodes, while
the nodes without metastasis at 16/84 with p =
0.002.13
In this study, analysis of ROC curve and sensi-
tivity and specificity graphs showed that VEGF lev-
els of 614.75 pg/ml had a highest sensitivity (80%)
and specificity (75%). The results suggest that se-
rum VEGF levels after radiation with a cut-off
614.75 pg/ml can be used to diagnose the response
of radiation therapy in cervical cancer, as mention
from the values of sensitivity, specificity, PPV, NPV
and sufficient accuracy, although the value of PLR
3.2 (<10) and NLR 0.26 (> 0.1)is still inadequate.
Hansgen et al which examined serum VEGF in
42 patients with locally advanced (FIGO II-IV)
squamous cell cervical cancer who were treated
with radiation, found that the concentration of
VEGF did not correlate with tumor stage. Compari-
son of VEGF levels with clinical outcome after 6
months of therapy with patients obtained a com-
plete response occurred significantly decreased
levels of VEGF (304 pg/ml ± 188) compared to pa-
tients with symptoms of tumor (892 pg/ml ± 756,
p <0.0005). Thus concluded that high serum VEGF
levels before therapy associated with poor res-
ponse to radiation therapy in locally advanced cer-
vical cancer.14-16
This study also found that the reduction in VEGF
serum levels pre and post-radiation were associ-
ated with a positive treatment response (p 0.01, CI
1.00 to 3.23). Thus if serum VEGF decrease after
radiation therapy, the therapeutic response will be
positive.
Loncaster et alexamined 100 patients with lo-
cally advanced cervical cancer (IB large lesions up
to IIIB), which consisted of 94 squamous cell car-
cinomas, 5 adenocarcinomas and 1 adenosqua-
mous carcinoma, found that there is no correlation
between VEGF expression with disease stage, tu-
mor differentiation, patient age and tumor radio-
sensitivity. In survival analysis, VEGF expression
was an independent prognostic factor of the most
significant (p = 0.001).6,13-17
This study suggests that serum VEGF levels post
radiation can be used to be a diagnostic factor for
response of radiation therapy in advanced cervical
cancer with AUC 92.5%, p 0.01 (CI: 0.81 to 1.00).
VEGF serum levels with cut-off 614.75 pg/ml had
a sensitivity of 80%, specificity 75%, PPV 94.12%,
NPV 42.86%, PLR 3.2, NLR 0.26 and accuracy
79.16%. And there is a significant correlation be-
tween the decrease in serum VEGF levels after ra-
diation therapy with a positive response of radia-
tion therapy (p 0.01, CI 1.00 to 3.23).
CONCLUSION
Examination of VEGF levels can be used to assess
the response of radiation therapy with a cut off
point of 614.75 pg/ml, with high sensitivity (80%)
and specificity(75%). There is also a significant
correlation between the decrease in serum VEGF
levels after radiation therapy with a positive re-
sponse of radiation therapy.
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